Androgen Receptor Biology: How Testosterone Signals in Cells

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

The androgen receptor (AR) belongs to the nuclear receptor superfamily — a class of ligand-activated transcription factors that regulate gene expression directly in the cell nucleus. Understanding AR biology is fundamental to research with any androgen or SARM, as it explains how testosterone produces its muscle-building effects in muscle, androgenic effects in prostate, and virilizing effects in skin/hair — and why different compounds can have different tissue-selectivity profiles at the same receptor.

AR Structure: Three Functional Domains#

The AR protein (919 amino acids, ~110 kDa) has three main domains:

1. N-terminal Domain (NTD) — AF-1 region:

• Activation function-1 (AF-1): primary transcriptional activation domain
• Unstructured in the absence of ligand; becomes organized upon ligand binding
• Interacts with coactivators (SRC-1, SRC-3, CBP/p300)
• Key for full transcriptional activity

2. DNA-Binding Domain (DBD):

• Two zinc finger motifs that bind DNA
• Recognizes Androgen Response Elements (AREs): consensus GnACTnnTGTTCT (palindromic half-sites)
• Dimerization interface: AR-AR homodimer forms on DNA
• Highly conserved — more than 70% identity with PR, GR DNA-binding domains (explains cross-receptor activity of some steroids)

3. Ligand-Binding Domain (LBD) — AF-2 region:

• C-terminal domain: ~300 amino acids with 11 α-helices
• Ligand-binding pocket accommodates androgen
• Helix-12 (H12): upon ligand binding, H12 repositions to form the coactivator-binding surface (the "AF-2 groove")
• H12 position determines agonism vs. antagonism: agonist → H12 closed → coactivator binds; antagonist → H12 open/displaced → no coactivator

The Activation Mechanism Step by Step#

1. Testosterone (or synthetic androgen) enters cell: Lipid-soluble steroids diffuse freely through phospholipid bilayer
2. Cytoplasmic AR is "inactive": Bound to heat-shock protein 90 (HSP90) and HSP70 — maintains AR in a ligand-receptive conformation
3. Ligand binds: Testosterone (or DHT, or synthetic androgen) occupies the LBD ligand-binding pocket
4. Conformational change: Helix-12 repositions → HSP90/70 dissociate → LBD AF-2 groove forms
5. N/C terminal interaction: NTD-AF1 interacts with LBD-AF2 in the same molecule → stabilizes activated conformation
6. Dimerization: Two AR monomers dimerize via DBD and NTD interactions
7. Nuclear import: NLS (Nuclear Localization Signal) exposed → importins escort AR dimer into nucleus
8. DNA binding: DBD contacts ARE half-sites in promoter/enhancer regions of androgen-responsive genes
9. Coactivator recruitment: AF-1 and AF-2 grooves recruit coactivator proteins → transcription machinery assembled
10. Gene transcription: RNA polymerase II recruited → target gene mRNA synthesized → translated to protein

Coactivator Proteins: Key to Tissue Selectivity#

The coactivator model explains SARM tissue selectivity:

Different tissues express different coactivators in different ratios:

• SRC-1 (Steroid Receptor Coactivator-1): abundant in muscle, brain; less in prostate
• SRC-3 (p300/CBP): abundant in prostate, bone

When a SARM (vs. DHT or testosterone) binds AR:

• The H12 conformation it induces may recruit SRC-1 well but SRC-3 poorly (or vice versa)
• Result: in SRC-1-expressing tissues (muscle) → full agonism; in SRC-3-expressing tissues (prostate) → partial agonism or weak activity
• This is the molecular basis for tissue-selective androgen receptor modulators (SARMs)

Androgen Response Elements (AREs)#

ARE consensus sequence: Imperfect palindrome: 5'-AGAACAnnnTGTTCT-3' (n = any nucleotide; spacing varies)

Classical AREs in androgen-regulated genes:

• Prostate-specific antigen (PSA/KLK3): two AREs in promoter — high AR sensitivity
• Muscle-specific AR target genes: typically weaker AREs → less sensitive to low testosterone levels
• SHBG (sex hormone-binding globulin): ARE in promoter; androgens suppress SHBG production

Context-dependence: The same ARE in different genomic contexts (different neighboring sequences, chromatin accessibility) produces different transcriptional outputs — same AR, different gene, different amplitude of response.

Tissue AR Expression and Research Relevance#

5α-Reductase expression determines local DHT:

• Prostate, skin, hair follicles: high 5α-reductase → testosterone → DHT (3–5× more potent AR agonist)
• Muscle: low 5α-reductase → testosterone is the primary AR ligand in muscle tissue
• This explains why 5α-reductase inhibitors (finasteride) reduce prostate/scalp effects without impairing muscle anabolism

Androgen Resistance and AR Research#

Complete Androgen Insensitivity Syndrome (CAIS) research model:

• Individuals with functional AR mutations: XY chromosomes but female phenotype
• Demonstrates: all anabolic and androgenic effects of testosterone require functional AR
• Research tool: AR-null cell lines or CAIS-derived cells as negative controls in AR signaling studies

AR mutations in prostate cancer:

• Gain-of-function mutations enable AR activation by non-androgen ligands (estrogen, progestogens)
• Castration-resistant prostate cancer (CRPC): AR amplified or mutated → active despite castrate testosterone levels
• Research applications: antiandrogen development (enzalutamide targets AR-LBD; apalutamide similar)

SARMs research rationale: Exploiting tissue-selective coactivator expression and ARE context to develop compounds that:

• Activate AR in muscle (SRC-1-dependent gene programs → hypertrophy)
• Avoid AR activation in prostate (SRC-3-dependent PSA/growth programs)
• Avoid androgenic effects in skin/scalp (5α-reductase resistant, or weak 5αR substrate)

Research Use Only. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science